4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population (Phase 2b), 70% injection-free through 52 weeksIn severe population (Phase 1/2a), 83% overall reduction in annualized injections through 52 weeks 4D-150 continues to be safe and well tolerated with intraocular inflammation (IOI) profile numerically similar (2.8% transient 1+ vitreous cells) to approved anti-VEGF ...